Gabor Mikala

division head

Hungary

Research Interests

Explore related searches

Professors in Hungary Professors in Medical Imaging Medical Imaging professors in Hungary

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gabor Mikala is the Head of Division at South-Pest Central Hospital - National Institute for Hematology and Infectious Diseases in Hungary. His research areas include multiple myeloma, thrombotic microangiopathy, and advancements in hematology treatment strategies. He has contributed to various publications focusing on lenalidomide resistance, disease markers in multiple myeloma, and patient outcomes from clinical studies. His recent work reflects a commitment to improving therapeutic approaches in hematological malignancies.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Magdalena Olszewska-Szopa

Medical University of Silesia

POLAND

View details

Marienn Réti

Head of the Innovative Cell Therapy Center (formerly: Apheresis and Stem Cell Processing Unit)

HUNGARY

View details

Fekete Mónika

Semmelweis University

HUNGARY

View details

Alessandro Gozzetti

University of Siena

ITALY

View details

Lidia Usnarska-Zubkiewicz

Wroclaw Medical University

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gabor Mikala

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Vendégszerkesztői előszó

Mit tanultunk a myelomáról az EHA 2024 kongresszusán?

PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma

Myeloma multiplex a 2023-as ASH-kongresszuson

IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma

Lenalidomid-rezisztencia eredményes áttörése 134 hónapos első vonalbeli lenalidomid-kezelést követően myelomás betegnél – Esetbemutatás

Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

Beszámoló az MHTT XXIX. kongresszusáról: Esztergom, 2023. május 25. – május 27.

Evaluation of Retinal Blood Flow in Patients with Monoclonal Gammopathy Using OCT Angiography

Miért szelektál a lenalidomid alkalmazása TP53 diszfunkció irányában?

Az idősödés során jellemző genetikai és epigenetikai változások és a gammopátiák progressziója •

Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment

Collaborators (5)

Magdalena Olszewska-Szopa

Marienn Réti

Fekete Mónika

Alessandro Gozzetti

Lidia Usnarska-Zubkiewicz

Make your next move.